A Cost-Utility Analysis of Drug Treatments in Patients With HBeAg-positive Chronic Hepatitis B in Thailand

BMC Health Services Research - United Kingdom
doi 10.1186/1472-6963-14-170
Full Text
Abstract

Available in full text

Categories
Health Policy
Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Cost-Effectiveness Analysis of Antiviral Treatments for HBeAg-Positive Chronic Hepatitis B in Canada

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2012English

IL28B Polymorphism Correlates With Active Hepatitis in Patients With HBeAg-Negative Chronic Hepatitis B

PLoS ONE
Multidisciplinary
2013English

Association of Serum Total Cholesterol With Pegylated Interferon-Α; Treatment in HBeAg-positive Chronic Hepatitis B Patients

Antiviral Therapy
Infectious DiseasesPharmacology
2018English

Immunoelectron Microscopic Observation of HBeAg in Hepatocytes of Patients With Chronic Hepatitis B.

Acta Hepatologica Japonica
Hepatology
1989English

Studies of Short-Term Prednisolone Therapy in Children With HBeAg Positive Chronic Type B Hepatitis.

Acta Hepatologica Japonica
Hepatology
1985English

The Clinical Significance of Quantitative HBSAG in Patients With HBEAG Negative Chronic Hepatitis B

Acta Medica Saliniana
Medicine
2019English

Editorial: Identifying Candidates for Pegylated Interferon Add-On to Entecavir Therapy in Patients With HBeAg-positive Chronic Hepatitis B

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2019English

Association of Virological Breakthrough and Clinical Outcomes in Entecavir-Treated HBeAg-positive Chronic Hepatitis B

PLoS ONE
Multidisciplinary
2019English

Baltic Post-Marketing Study of Pegilated Interferon Α-2a 40 KD Efficacy and Safety in Patients With HBeAg–Positive and HBeAg – Negative Chronic Hepatitis B

Virology & Mycology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy